Clinical trials
PSMA Positive Tumors or Tumor Tissues clinical trials
Below are recruiting psma positive tumors or tumor tissues clinical trials, each written for real people, not researchers. We’re tracking 1,319 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07069595RecruitingPhase 2
Blood test for breast cancer survivors at risk of recurrence
This trial uses a simple blood test to look for leftover cancer DNA in people with triple-negative breast cancer who still have disease after chemotherapy and surgery. It aims to catch any early signs of the cancer coming back.
Chapel Hill, North CarolinaAges 18 years+ - NCT07101562Recruiting
Repairing hip bone damage with your own stem cells
This study is testing a new way to repair the damaged bone in your hip by using your own bone marrow stem cells. You may be a candidate if you have femoral head necrosis (hip bone death) that did not get better with standard treatments and you are otherwise healthy enough for surgery.
Xinxiang, HenanAges 20–65 - NCT07106723RecruitingPhase 2
Study of stem cell transplant and CD7-CART for T-cell lymphoma
This trial combines your own stem cells (collected before) with a special immune cell therapy (CD7-CART) to treat T-cell lymphoma or leukemia. It may help people with high-risk or hard-to-treat disease.
Tianjin, Tianjin MunicipalityAges 18–65 - NCT07111000Recruiting
Epley maneuver for dizziness in the emergency room
This study tests whether a simple head movement called the Epley maneuver can help treat dizziness caused by a common inner ear condition (BPPV) in the emergency room. If you have short episodes of vertigo that last less than 2 minutes, you may be able to join.
BeirutAges 18 years+ - NCT07112222RecruitingPhase 1/Phase 2
Study of LM-350 for advanced solid tumors
This trial tests an experimental drug called LM-350 for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug can shrink tumors or slow their growth.
Wollongong, New South WalesAges 18 years+ - NCT07121998Recruiting
Study of resistance to alkylating chemotherapy in endocrine tumors
This study looks at why some endocrine tumors (tumors in hormone-making glands) stop responding to a specific type of chemotherapy called alkylating agents. Researchers will collect tissue samples to understand how the tumor changes and why the medicine stops working.
UppsalaAges 18 years+ - NCT07128641RecruitingPhase 2
Odronextamab for early follicular lymphoma without prior treatment
This trial tests a new immunotherapy drug, odronextamab, for people with slow-growing follicular lymphoma that hasn't been treated yet and isn't causing big problems. It aims to see if the drug can control the cancer with fewer side effects.
Boston, MassachusettsAges 18 years+ - NCT07134192Recruiting
Using a dye to guide sarcoma surgery
This trial tests a special dye that helps surgeons see the edges of sarcoma tumors during surgery. It may help them remove all the cancer while saving healthy tissue.
Aarhus NAges 18 years+ - NCT07145255RecruitingPhase 1/Phase 2
Study of MBRC-201 for advanced solid tumors
This trial tests a new drug, MBRC-201, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find the best dose and see if it helps shrink tumors or slow their growth.
San Francisco, CaliforniaAges 18 years+ - NCT07154706RecruitingPhase 3
Taletrectinib vs placebo after surgery for ROS1-positive lung cancer
This trial tests whether taletrectinib (a targeted pill) can help prevent lung cancer from coming back after surgery in people whose tumors have a ROS1 gene change. You would take either taletrectinib or a placebo (inactive pill) for about a year after surgery.
Los Angeles, CaliforniaAges 18 years+ - NCT07162012RecruitingEarly Phase 1
Cell therapy for EBV-positive lymphoma
This trial tests a new cell therapy (TCR-T cells) for people with EBV-positive lymphoma that has not responded to standard treatments or has come back. The therapy uses your own immune cells that have been specially trained to find and attack cancer cells carrying the EBV virus.
ShanghaiAges 18–70 - NCT07168616Recruiting
PSMA PET imaging for active surveillance in low-risk prostate cancer
This study uses a special imaging test (PSMA PET/CT) to better see if men with low-risk prostate cancer are good candidates for active surveillance (monitoring instead of immediate treatment). It helps doctors decide if watching the cancer closely is safe.
Istanbul, TurkeyAges 18 years+ - NCT07172685Recruiting
Triple therapy plus HIFU for high-tumor-burden prostate cancer
This trial tests a combination of hormone therapy, chemotherapy (docetaxel), and a targeted drug (apalutamide) with a focused ultrasound procedure (HIFU) for men with prostate cancer that has spread to many bones or organs. It may help control the cancer more effectively.
Jinan, ShandongAges 18 years+ - NCT07176312RecruitingPhase 2
Zanidatamab with pembrolizumab and chemo for HER2+ and PD-L1+ stomach cancer
This trial tests a new combination of targeted therapy (zanidatamab), immunotherapy (pembrolizumab), and chemotherapy for people with HER2-positive and PD-L1-positive advanced stomach or gastroesophageal cancer. It aims to see if this combination is more effective than current treatments.
BerlinAges 18 years+ - NCT07179744Recruiting
Skipping radiation for low-risk node-positive breast cancer
This trial tests whether some women with low-risk breast cancer that has spread to a few lymph nodes can safely skip radiation therapy after surgery. It aims to reduce side effects while keeping the cancer from coming back.
Guangzhou, GuangdongAges 18–70 - NCT07183319RecruitingPhase 2
ctDNA test in advanced bladder cancer
This trial studies how a blood test that looks for tumor DNA (ctDNA) can help guide treatment in people with advanced bladder cancer that cannot be removed by surgery or has spread. It aims to see if the test results can help doctors choose the best therapy.
Oklahoma City, OklahomaAges 18 years+ - NCT07189871RecruitingPhase 1/Phase 2
177Lu-BetaBart for advanced solid tumors
This trial tests a new radioactive drug, 177Lu-BetaBart, for people with certain advanced solid tumors that have stopped responding to other treatments. The goal is to see if it can shrink tumors or slow their growth.
Dothan, AlabamaAges 18 years+ - NCT07192068RecruitingPhase 2
Zanidatamab for HER2-altered solid tumors
This trial tests a drug called zanidatamab in people with certain cancers (endometrial, colorectal, head & neck, non-small cell lung, or sarcoma) that have a specific change in the HER2 gene. It's for those whose cancer has spread or can't be removed and who have tried at least one prior treatment.
AngersAges 18 years+ - NCT07195227RecruitingPhase 2
Camizestrant plus ribociclib for advanced breast cancer
This trial tests a combination of two drugs, camizestrant and ribociclib, for people with a certain type of advanced breast cancer (HR+/HER2-). It is for those whose cancer has grown or spread despite previous hormone therapy. The goal is to see if this new combination can help control the cancer.
DessauAges 18 years+ - NCT07197645RecruitingPhase 1
Samarium for pain from bone cancer
This trial tests a new radioactive drug (samarium) given once to reduce severe bone pain from cancer that has spread to the bones. It is for people whose pain is not controlled by current treatments and who cannot have standard radiation.
Miami, FloridaAges 18 years+ - NCT07199959Recruiting
Study on why entrectinib stops working in ROS1 lung cancer
This study looks at why the targeted drug entrectinib stops working in some people with ROS1-positive lung cancer. Participants will give blood or tumor samples before and after treatment to help researchers understand resistance.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07207070RecruitingPhase 3
New drug combination for PIK3CA-mutated breast cancer
This trial tests a new combination of two drugs (JS105 plus dalpiciclib and fulvestrant) against a standard combination (dalpiciclib plus fulvestrant) for people whose breast cancer has a PIK3CA mutation. The goal is to see if adding JS105 helps control the cancer longer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07214532Recruiting
Guiding CDK4/6 inhibitor use by a blood test in breast cancer
This trial is for women and men with early-stage, hormone-positive, HER2-negative breast cancer. It uses a blood test (Signatera) to detect tiny amounts of cancer DNA and only starts a CDK4/6 inhibitor (ribociclib or abemaciclib) if the test shows cancer DNA is present.
Birmingham, AlabamaAges 18 years+ - NCT07215611Recruiting
Financial stress after sarcoma surgery study
This study looks at financial problems patients may have after surgery for bone or soft tissue sarcoma. It aims to understand how treatment costs affect patients and help find ways to support them.
Houston, TexasAges Any age
Hear when a new PSMA Positive Tumors or Tumor Tissues trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for psma positive tumors or tumor tissues?
- Yes. Clin2 currently lists 1,319 recruiting psma positive tumors or tumor tissues studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a psma positive tumors or tumor tissues trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a psma positive tumors or tumor tissues trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.